Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(6E,11E)-heptadeca-6,11-diene-9,9-diylbis(phosphonic acid) is a synthetic small molecule belonging to the bisphosphonate class. It is structurally characterized by a 17-carbon chain with two phosphonic acid groups at the 9-position and conjugated double bonds at positions 6 and 11. The compound has been studied as an experimental agent and is not approved for clinical use. Its mechanism of action involves inhibition of geranylgeranyl pyrophosphate synthase (GGPS1), an enzyme critical in the biosynthesis of geranylgeranyl pyrophosphate—a key intermediate in protein prenylation pathways. This mechanism suggests potential utility in modulating processes dependent on protein prenylation such as cell signaling or viral replication[3][5][10]. There are no known approved indications or ongoing clinical trials for this compound.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (6E,11E)-heptadeca-6,11-diene-9,9-diylbis(phosphonic acid).